TMCnet News
Cynapsus Therapeutics Announces Change of Auditor(Marketwire (Canada) Via Acquire Media NewsEdge) TORONTO, ONTARIO--(Marketwired - Sept. 19, 2014) - Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company") (TSX VENTURE:CTH)(OTCQX:CYNAF) announces that it has changed its auditor. McGovern, Hurley, Cunningham, LLP (the "Former Auditor") has resigned at the request of the Company, effective September 18, 2014. The Directors of the Company have appointed Ernst & Young LLP (the "Successor Auditor") of Toronto, Ontario as auditor for the Company, effective September 19, 2014 until the close of the Company's next Annual General Meeting. The change in auditor has been approved by Cynapsus' Audit Committee and Board of Directors. There were no reservations in the Former Auditor's reports in connection with the two most recently-completed fiscal years or for any period subsequent to the most recently-completed period for which an audit report was issued and preceding the date of the Former Auditor's resignation. There are no reportable events between Cynapsus and the Former Auditor as defined in National Instrument 51-102 - Continuous Disclosure Obligations. About Cynapsus Therapeutics Cynapsus is a specialty pharmaceutical company developing a convenient and easy to use sublingual (oral) thin film strip for the acute rescue of OFF motor symptoms of Parkinson's disease. Cynapsus' drug candidate, APL-130277, is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug (in the United States, Europe, Japan and other countries) to rescue patients from OFF episodes. Cynapsus is focused on maximizing the value of APL-130277 by completing pivotal studies in advance of a New Drug Application ("NDA") expected to be submitted in 2016. Over one million people in the U.S. and an estimated 4 to 6 million people globally suffer from Parkinson's disease. Parkinson's disease is a chronic and progressive neurodegenerative disease that impacts motor activity, and its prevalence is increasing with the aging of the population. Based on a recent study and the results of the Corporation's Global 500 Neurologists Survey, it is estimated that between 25 percent and 50 percent of patients experience OFF episodes in which they have impaired movement or speaking capabilities. Current medications only control the disease's symptoms, and most drugs become less effective over time as the disease progresses. More information about Cynapsus (TSX VENTURE:CTH)(OTCQX:CYNAF) is available at www.cynapsus.ca and at the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com. Forward-Looking Statements This announcement contains "forward-looking statements" within the meaning of applicable securities laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Cynapsus to be materially different from those expressed or implied by such forward-looking statements, including but not limited to those risks and uncertainties relating to Cynapsus' business disclosed under the heading "Risk Factors" in its March 26, 2014, Annual Information Form and its other filings with the various Canadian securities regulators which are available online at www.sedar.com. Although Cynapsus has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Cynapsus does not undertake to update any forward-looking statements, except in accordance with applicable securities laws. Neither the TSX Venture Exchange nor the OTCQX International has approved or disapproved of the contents of this press release. FOR FURTHER INFORMATION PLEASE CONTACT: Cynapsus Therapeutics Anthony Giovinazzo President and CEO (416) 703-2449 x225 [email protected] Cynapsus Therapeutics Andrew Williams COO & CFO (416) 703-2449 x253 [email protected] www.cynapsus.ca Source: Cynapsus Therapeutics Inc. |